Noradrenaline Sintetica (Noradrenaline Tartrate)

Noradrenaline Tartrate directly stimulates alpha‑1, alpha‑2 and beta‑1 adrenergic receptors. Alpha‑1 activation causes peripheral vasoconstriction, alpha‑2 modulates sympathetic outflow, and beta‑1 increases heart contractility and rate, together elevating blood pressure and cardiac output.

The dosing regimen for Noradrenaline Sintetica is individualized. A qualified prescriber determines the infusion rate and titration schedule based on the patient’s hemodynamic status, underlying condition and response to therapy.

Safety data for Noradrenaline Sintetica in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where applicable) and necessary import documentation.

Noradrenaline is generally preferred over dopamine because it provides stronger vasoconstriction with less tachyarrhythmia risk. Compared with phenylephrine, it also offers beta‑1 stimulation, which supports cardiac output, making it a more balanced choice for many shock states.

Noradrenaline Sintetica must be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the product. Before use, allow the solution to reach room temperature if required, and inspect for particulate matter.

The drug is given as an intravenous infusion, typically via a central or large peripheral line. Infusion rates are titrated to achieve target blood pressure, and the solution should be administered using a calibrated infusion pump to ensure accurate dosing.

Clinicians should monitor for myocardial ischemia, severe hypertension, and tissue necrosis at the infusion site. Early detection of these events allows prompt adjustment of the infusion or discontinuation to prevent irreversible damage.

Noradrenaline is contraindicated in patients with known hypersensitivity to noradrenaline or any formulation excipients, and in those receiving monoamine oxidase inhibitors. Caution is also advised in patients with uncontrolled hypertension or severe peripheral vascular disease.